Sandoz Group (OTCMKTS:SDZNY) Hits New 12-Month High – What’s Next?

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY)’s share price hit a new 52-week high on Wednesday . The company traded as high as $75.4950 and last traded at $75.4950, with a volume of 966 shares. The stock had previously closed at $73.77.

Analyst Upgrades and Downgrades

Separately, Barclays raised Sandoz Group to a “strong-buy” rating in a research report on Monday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy”.

Sandoz Group Stock Up 0.0%

The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.82 and a current ratio of 1.29. The firm’s 50-day moving average is $68.21 and its 200 day moving average is $61.62.

About Sandoz Group

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.